Physician profile
Aditya Parshad
NPI 1487648424
$4,418.31
in general payments reported to CMS, 2019-2025
38 companies · $396 in 2025
The $396 reported for 2025 was more than what 75% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $514 · 2020: $561 · 2021: $954 · 2022: $1,054 · 2023: $480 · 2024: $460 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,323 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,322.71 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $864.30 | 2019-2023 | |
| Exeltis, USA INC. | $429.15 | 2019-2025 | Slynd |
| Astellas Pharma US INC | $418.06 | 2021-2025 | Veozah |
| Horizon Therapeutics Plc | $236.17 | 2019-2021 | |
| Aspira Women'S Health INC | $220.84 | 2021-2022 | |
| Therapeuticsmd, INC. | $203.41 | 2019-2022 | |
| Novo Nordisk INC | $175.09 | 2024-2025 | Wegovy |
| Sage Therapeutics, LLC | $172.54 | 2024-2025 | Zurzuvae |
| Avion Pharmaceuticals | $165.22 | 2019-2023 | Balcoltra |
| Currax Pharmaceuticals LLC | $158.75 | 2020-2023 | Onzetra Xsail, Contrave |
| Sumitomo Pharma America, INC. | $153.10 | 2023-2025 | Myfembree, Gemtesa |
| Encore Dermatology INC. | $126.48 | 2019 | |
| Scynexis, INC. | $116.19 | 2022 | |
| Millicent US INC | $113.16 | 2020-2023 | Intrarosa, Femring |
| Revance Therapeutics, INC. | $81.77 | 2024 | Daxxify |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $70.11 | 2022-2024 | Acessa Provu System, Omni Hysteroscope, Novasure |
| Myovant Sciences INC. | $68.60 | 2021-2022 | |
| Coopersurgical, INC. | $66.56 | 2021-2023 | Paragard T 380a |
| Bausch Health US, LLC | $53.66 | 2021-2022 | |
| Myriad Women'S Health, INC. | $42.40 | 2023 | |
| Mayne Pharma Commercial LLC | $40.84 | 2022-2023 | |
| Baxter Healthcare | $40.63 | 2025 | Seprafilm |
| Agile Therapeutics, INC. | $38.40 | 2021 | |
| Pfizer INC. | $35.96 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $35.51 | 2022 | |
| Channel Medsystems, INC. | $33.53 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.38 | 2019 | |
| Shield Therapeutics INC | $30.02 | 2023 | Accrufer |
| Lupin INC. | $29.85 | 2019 | |
| Allergan, INC. | $29.02 | 2019-2020 | |
| Heron Therapeutics, INC. | $25.05 | 2022 | |
| Vertical Pharmaceuticals, LLC | $22.44 | 2019 | |
| Boston Scientific Corporation | $22.00 | 2022 | |
| Amag Pharmaceuticals, INC. | $17.11 | 2019 | |
| Mission Pharmacal Company | $15.77 | 2019 | |
| Smith+Nephew, INC. | $13.62 | 2019 | |
| Assertio Therapeutics, INC. | $11.69 | 2019 | |
| Meditrina | $10.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditya Parshad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.